Report in English with a Dutch summary (KCE reports 63A)

40 Breast Cancer KCE reports 63
100. Smith, I., et al., 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2positive
breast cancer: a randomised controlled trial. Lancet, 2007. 369(9555): p. 29-36.
101. Wolff, A.C., et al., American Society of Clinical Oncology/College of American Pathologists
guideline recommendations for human epidermal growth factor receptor 2 testing in breast
cancer. J Clin Oncol, 2007. 25(1): p. 118-45.
102. Klijn, J.G., et al., Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH)
agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of
four randomized trials. J Clin Oncol, 2001. 19(2): p. 343-53.
103. Ferretti, G., et al., Second- and third-generation aromatase inhibitors as first-line endocrine
therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised
trials. Br J Cancer, 2006. 94(12): p. 1789-96.
104. Eisen, A., et al., Role of aromatase inhibitors in the treatment of postmenopausal women
with metastatic breast cancer., C.C. Ontario, Editor. 2003, Cancer Care Ontario: Toronto.
105. Farquhar, C., et al., High dose chemotherapy and autologous bone marrow or stem cell
transplantation versus conventional chemotherapy for women with metastatic breast cancer.
Cochrane Database Syst Rev, 2005(3): p. CD003142.
106. Carrick, S., et al., Platinum containing regimens for metastatic breast cancer. Cochrane
Database Syst Rev, 2004(3): p. CD003374.
107. Carrick, S., et al., Single agent versus combination chemotherapy for metastatic breast
cancer. Cochrane Database of Systematic Reviews, 2005(2): p. CD003372.
108. Ghersi, D., et al., Taxane containing regimens for metastatic breast cancer. Cochrane
Database Syst Rev, 2003(3): p. CD003366.
109. Marty, M., et al., Randomized phase II trial of the efficacy and safety of trastuzumab combined
with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic
breast cancer administered as first-line treatment: the M77001 study group.[see comment]. Journal
of Clinical Oncology, 2005. 23(19): p. 4265-74.
110. Pavlakis, N., R. Schmidt, and M. Stockler, Bisphosphonates for breast cancer. Cochrane
Database Syst Rev, 2005(3): p. CD003474.
111. Warr, D., M. Johnston, and Breast Cancer Disease Site Group, Use of Bisphosphonates in
Women with Breast Cancer. Practice Guideline Report #1-11., C.C. Ontario, Editor. 2004,
Cancer Care Ontario: Toronto.
112. Badger, C., et al., Physical therapies for reducing and controlling lymphoedema of the limbs.
Cochrane Database Syst Rev, 2004(4): p. CD003141.
113. McNeely, M.L., et al., Effects of exercise on breast cancer patients and survivors: a systematic
review and meta-analysis. Cmaj, 2006. 175(1): p. 34-41.
114. von Schoultz, E. and L.E. Rutqvist, Menopausal hormone therapy after breast cancer: the
Stockholm randomized trial. J Natl Cancer Inst, 2005. 97(7): p. 533-5.
115. Edwards, A.G., S. Hailey, and M. Maxwell, Psychological interventions for women with
metastatic breast cancer. Cochrane Database Syst Rev, 2004(2): p. CD004253.
116. Lane, L.G. and L.L. Viney, The effects of personal construct group therapy on breast cancer
survivors. Journal of Consulting & Clinical Psychology, 2005. 73(2): p. 284-92.
117. Savard, J., et al., Randomized study on the efficacy of cognitive-behavioral therapy for
insomnia secondary to breast cancer, part II: Immunologic effects. Journal of Clinical Oncology,
2005. 23(25): p. 6097-106.
118. Taylor, K.L., et al., Psychological adjustment among African American breast cancer patients:
one-year follow-up results of a randomized psychoeducational group intervention. Health
Psychology, 2003. 22(3): p. 316-23.
119. Antoni, M.H., et al., Reduction of cancer-specific thought intrusions and anxiety symptoms
with a stress management intervention among women undergoing treatment for breast cancer.
American Journal of Psychiatry, 2006. 163(10): p. 1791-7.